Expanded Access Programmes Global Congress 2022 Europe
01 Mar,2022 - 02 Mar,2022
London, United Kingdom
A Little Teaser
2nd Expanded Access Programmes Global Congress 2022 Europe
Expanded Access Programmes also known by other terms such as compassionate use, early access, managed access, named-patient access, or pre-approval access is a potential pathway for a patient with an immediately life-threatening illness or severely debilitating disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) before they are reviewed and approved by a regulatory authority.
When it is not possible for a patient to participate in a clinical trial and all other available medical options have been exhausted, the patient’s physician may seek special access to investigational medicine outside of the clinical trial setting. As investigational drugs have not yet received regulatory approval, it is very important to remember that their potential risks and benefits are not yet established. In general, the person and his or her doctor must apply for access to the investigational product, the company has to choose to cooperate, and the medicines regulatory agency needs to agree that the risks and possible benefits of the drug or device are understood well enough to determine if putting the person at risk has sufficient potential benefit.
Please click the link on the right to visit the Event Website or to Register
The Expanded Access Programmes congress will be Co-located with the RWE, Market Access, Pricing & Reimbursement Congress.
Joint Networking at the Exhibit area.
Take advantage of networking with attendees and participants with receptive mindsets, from both events.
To find out about the range of branding, Exhibit, and Sponsorship Options, get in touch.
Sponsorship Opportunities: email@example.com
For more information: firstname.lastname@example.org
Tel No: +44 (0) 207 193 3485